Literature DB >> 15913564

Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.

Daniele Grazziotin Soares1, Nadine Paese Poletto, Diego Bonatto, Mirian Salvador, Gilberto Schwartsmann, João Antonio Pêgas Henriques.   

Abstract

Ecteinascidin 743 (ET-743) is a promising antitumoral drug for the treatment of soft tissues sarcomas, becoming a good candidate for clinical trials. However, the molecular mechanism of how ET-743 induces cells death is poorly understood. The chemical structure of ET-743 suggests that it can form cytotoxic cross-links with proteins and DNA. Experiments with Escherichia coli and mammalian cells indicate that the nucleotide excision repair (NER) pathway promotes ET-743 cytotoxicity. We therefore analyzed cytotoxicity and tolerance to ET-743 in the yeast Saccharomyces cerevisiae, defective for NER and/or base excision repair (BER), either in single mutants or in combination with mutant alleles of genes encoding proteins involved in DNA translesion synthesis (TLS) and homologous recombination (HR). Treatment of haploid and diploid S. cerevisiae strains with ET-743 led to induced mutagenesis, mitotic gene conversion, and crossing-over. The results indicated that yeast strains lacking endonucleases of the NER and BER pathways are especially resistant for ET-743. The mutagenesis data points to a weak mutagenic activity of ET-743 in both WT and strains lacking BER/NER endonuclease, and that a mutant blocked in both BER and TLS totally lacks induced mutagenesis. The diploid strain shows an increase in the frequencies of crossing-over and mitotic recombination. These data lead us to propose a model for ET-743 action in eukaryotic cells, where the presence of BER and NER endonucleases results in cell death. However, ET-743 damage can be tolerated in BER and/or NER mutants by TLS (error-prone) or in combination with HR (error-free).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913564     DOI: 10.1016/j.bcp.2005.04.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Drug discovery from natural sources.

Authors:  Young-Won Chin; Marcy J Balunas; Hee Byung Chai; A Douglas Kinghorn
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

2.  Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Authors:  Daniele Grazziotin Soares; Alexandre E Escargueil; Virginie Poindessous; Alain Sarasin; Aimery de Gramont; Diego Bonatto; João Antonio Pêgas Henriques; Annette K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-26       Impact factor: 11.205

Review 3.  Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.

Authors:  José Antonio López-Guerrero; Ignacio Romero; Andrés Poveda
Journal:  Chin J Cancer       Date:  2015-01

4.  Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michela Romano; Matteo Giovanni Della Porta; Anna Gallì; Nicolò Panini; Simonetta Andrea Licandro; Ezia Bello; Ilaria Craparotta; Vittorio Rosti; Elisa Bonetti; Richard Tancredi; Marianna Rossi; Laura Mannarino; Sergio Marchini; Luca Porcu; Carlos M Galmarini; Alberto Zambelli; Marco Zecca; Franco Locatelli; Mario Cazzola; Andrea Biondi; Alessandro Rambaldi; Paola Allavena; Eugenio Erba; Maurizio D'Incalci
Journal:  Br J Cancer       Date:  2017-01-10       Impact factor: 7.640

5.  Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Authors:  B Colmegna; S Uboldi; R Frapolli; S A Licandro; N Panini; C M Galmarini; Nadia Badri; V J Spanswick; J P Bingham; Konstantinos Kiakos; E Erba; J A Hartley; M D'Incalci
Journal:  Br J Cancer       Date:  2015-12-03       Impact factor: 7.640

6.  Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.

Authors:  Sonia Ávila-Arroyo; Gema Santamaría Nuñez; Luis Francisco García-Fernández; Carlos M Galmarini
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.